We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
(+9.9%)
Cap. Flow
-$182M
Cap. Flow
% of AUM
-9.13%
Top 10 Holdings %
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$21.3M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$21.2M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$16.1M |
| 4 |
Biogen
BIIB
|
+$9.79M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$8.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$33.1M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$7.45M |
| 3 |
MBLY
Mobileye N.V.
MBLY
|
+$7.26M |
| 4 |
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
|
+$5.86M |
| 5 |
ASXC
Asensus Surgical, Inc.
ASXC
|
+$5.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 11.94% |
| 2 | Consumer Staples | 0.06% |
| 3 | Industrials | 0.04% |
| 4 | Technology | 0.04% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Eli Lilly
LLY
$1.07T
| $209M | 10.43% |
28,962
+5,168
| +22% | +$391K |
|
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $189M | 9.44% |
10,176
+1,176
| +13% | +$229K |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| – | – |
0
| – | – |
|
|
4
CALL
Biogen
BIIB
$29.9B
| $173M | 8.68% |
6,663
+3,226
| +94% | +$852K |
|
5
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $162M | 8.12% |
17,673
+174
| +1% | +$15.2K |
|
6
CALL
AbbVie
ABBV
$458B
| $79.8M | 3.99% |
13,966
+8,227
| +143% | +$459K |
|
7
CALL
Gilead Sciences
GILD
$161B
| $77.5M | 3.88% |
8,440
-1,314
| -13% | -$118K |
|
8
CALL
Johnson & Johnson
JNJ
$635B
| $69M | 3.45% |
+6,374
| New | +$660K |
|
9
CALL
HCA Healthcare
HCA
$84.8B
| $53.1M | 2.65% |
6,798
+6,174
| +989% | +$431K |
|
|
10
PUT
Amgen
AMGN
$203B
| $51.6M | 2.58% |
+3,441
| New | +$511K |
|
|
11
PUT
Eli Lilly
LLY
$1.07T
| $34.6M | 1.73% |
4,803
+1,999
| +71% | +$151K |
|
|
MDCO
12
CALL
DELISTED
Medicines Co
MDCO
| $30.2M | 1.51% |
9,501
+3,153
| +50% | +$103K |
|
13
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
| $27.6M | 1.38% |
5,337
-543
| -9% | -$26.7K |
|
|
14
PUT
Biogen
BIIB
$29.9B
| $27.4M | 1.37% |
1,052
-188
| -15% | -$49.7K |
|
|
15
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $22.4M | 1.12% |
+108,899
| New | +$21.2M |
|
|
16
PUT
Johnson & Johnson
JNJ
$635B
| $22.3M | 1.12% |
+2,061
| New | +$213K |
|
17
CALL
Edwards Lifesciences
EW
$47.6B
| $21.9M | 1.09% |
+7,431
| New | +$205K |
|
|
18
Amgen
AMGN
$203B
| $21.5M | 1.08% |
+143,486
| New | +$21.3M |
|
|
19
PUT
Regeneron Pharmaceuticals
REGN
$68.8B
| $21.2M | 1.06% |
+588
| New | +$242K |
|
|
20
PUT
Edwards Lifesciences
EW
$47.6B
| $19.4M | 0.97% |
6,603
+3,003
| +83% | +$82.9K |
|
|
21
PUT
Sarepta Therapeutics
SRPT
$1.66B
| $17.2M | 0.86% |
8,824
+5,522
| +167% | +$96.5K |
|
22
Plus Therapeutics
PSTV
$26.4M
| $14.3M | 0.72% |
3
-3
| -50% | -$1.5M |
|
|
23
Regeneron Pharmaceuticals
REGN
$68.8B
| $14.1M | 0.7% |
+39,027
| New | +$16.1M |
|
|
24
Sarepta Therapeutics
SRPT
$1.66B
| $9.88M | 0.49% |
+505,937
| New | +$8.84M |
|
|
25
Biogen
BIIB
$29.9B
| $9.65M | 0.48% |
+37,077
| New | +$9.79M |
|
Similar funds
NA
CG
OC
ICCON
PCM
CAS
CM
MCMC
Sabby Management's Q1 2016 Portfolio in Review
As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.
Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.
- Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
- Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
- Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
- Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
- Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
- Sabby Management opened 102 new positions and closed 120 in Q1 2016.
- Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.
Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.